Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh‑resolution mass spectrometry

June 2023

Authors: MD, PhD, FEBU Tadeusz Ossolinski, MD, PhD, FEBU Krzysztof Ossoliński, MD, FEBU Anna Ossolińska, Joanna Nizioł 1, Aneta Płaza-Altamer 3 4, Artur Kołodziej 3 4, Anna Nieczaj 3, Tomasz Ruman 3

Abstract

Bladder cancer (BC) is a prevalent urological malignancy with high risks of mortality and recurrence. Routine follow-up with cystoscopy is invasive and costly. In this study, 200 human urine samples (100 BC patients, 100 controls) were analyzed using UHPLC-UHRMS, followed by univariate and multivariate statistical analyses with external validation. The research identifies urinary metabolites distinguishing BC from controls, considering tumor stage, grade, age, and gender, demonstrating potential for non-invasive diagnostics and disease monitoring

Full link below:

Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry – PubMed